The Italian Association of Haemophilia Centres reviewed and finally approved in November 2004 the new Italian Guidelines for the diagnosis and treatment of patients with clotting factor inhibitors. The recommendations have been based on the identification of levels of clinical evidence derived from the systematic review carried out in 2003 by the School of Health and Related Research, the University of Sheffield, UK, and further integrated by clinical studies published from 2003 to 2004. The Italian guidelines consist of six major domains concerning inhibitor definition, epidemiology, risk factors, diagnosis, inhibitor eradication, management of bleeding episodes, in patients with congenital and acquired coagulation disorders, with 121 statements, 59 synthesis and 54 recommendations. We report here recommendations and open issues concerning the diagnosis and monitoring of inhibitors, inhibitor eradication and the management of bleeding in patients with haemophilia A and B. (copyright) 2005 Blackwell Publishing Ltd.

Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors / A. Gringeri, P.M. Mannucci. - In: HAEMOPHILIA. - ISSN 1351-8216. - 11:6(2005), pp. 611-619.

Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors

A. Gringeri
Primo
;
P.M. Mannucci
Ultimo
2005

Abstract

The Italian Association of Haemophilia Centres reviewed and finally approved in November 2004 the new Italian Guidelines for the diagnosis and treatment of patients with clotting factor inhibitors. The recommendations have been based on the identification of levels of clinical evidence derived from the systematic review carried out in 2003 by the School of Health and Related Research, the University of Sheffield, UK, and further integrated by clinical studies published from 2003 to 2004. The Italian guidelines consist of six major domains concerning inhibitor definition, epidemiology, risk factors, diagnosis, inhibitor eradication, management of bleeding episodes, in patients with congenital and acquired coagulation disorders, with 121 statements, 59 synthesis and 54 recommendations. We report here recommendations and open issues concerning the diagnosis and monitoring of inhibitors, inhibitor eradication and the management of bleeding in patients with haemophilia A and B. (copyright) 2005 Blackwell Publishing Ltd.
Italy ; anaphylaxis ; bleeding ; clinical trial ; cost benefit analysis ; cost effectiveness analysis ; disseminated intravascular clotting ; dose response ; drug cost ; drug efficacy ; drug half life ; drug hypersensitivity ; drug megadose ; drug potentiation ; drug safety ; drug substitution ; evidence based medicine ; hemophilia A ; hemophilia B ; human ; optimal drug dose ; oral bleeding ; practice guideline ; priority journal ; review ; substitution therapy ; systematic review ; therapy resistance ; thrombosis ; treatment failure ; urinary tract obstruction ; activated prothrombin complex ; antifibrinolytic agent ; blood clotting factor 8 concentrate ; blood clotting factor 9 concentrate ; immunoglobulin ; immunosuppressive agent ; recombinant blood clotting factor 7a
Settore MED/09 - Medicina Interna
2005
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/14564
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 62
social impact